Search

Your search keyword '"Landsberg, Jennifer"' showing total 395 results
Start Over Author "Landsberg, Jennifer"
395 results on '"Landsberg, Jennifer"'

2. Shortened progression free and overall survival to immune-checkpoint inhibitors in BRAF-, RAS- and NF1- (“Triple”) wild type melanomas

Author

Jansen, Philipp, Galetzka, Wolfgang, Lodde, Georg C., Standl, Fabian, Zaremba, Anne, Herbst, Rudolf, Terheyden, Patrick, Utikal, Jochen, Pföhler, Claudia, Ulrich, Jens, Kreuter, Alexander, Mohr, Peter, Gutzmer, Ralf, Meier, Friedegund, Dippel, Edgar, Weichenthal, Michael, Placke, Jan-Malte, Landsberg, Jennifer, Möller, Inga, Sucker, Antje, Paschen, Annette, Hadaschik, Eva, Zimmer, Lisa, Livingstone, Elisabeth, Schadendorf, Dirk, Ugurel, Selma, Stang, Andreas, and Griewank, Klaus G.

Published
2024
Full Text
View/download PDF

3. CTLA4 DNA methylation is associated with CTLA-4 expression and predicts response to immunotherapy in head and neck squamous cell carcinoma

Author

Hoffmann, Friederike, Franzen, Alina, de Vos, Luka, Wuest, Lennert, Kulcsár, Zsófi, Fietz, Simon, Maas, Alexander Philippe, Hollick, Sarah, Diop, Marie Yatou, Gabrielpillai, Jennis, Vogt, Timo, Kuster, Pia, Zarbl, Romina, Dietrich, Joern, Kristiansen, Glen, Brossart, Peter, Landsberg, Jennifer, Strieth, Sebastian, and Dietrich, Dimo

Published
2023
Full Text
View/download PDF

4. ICOS DNA methylation regulates melanoma cell-intrinsic ICOS expression, is associated with melanoma differentiation, prognosis, and predicts response to immune checkpoint blockade

Author

Ralser, Damian J., Herr, Emmanuelle, de Vos, Luka, Kulcsár, Zsófi, Zarbl, Romina, Klümper, Niklas, Gielen, Gerrit H., Maas, Alexander Philippe, Hoffmann, Friederike, Dietrich, Jörn, Kuster, Pia, Mustea, Alexander, Glodde, Nicole, Kristiansen, Glen, Strieth, Sebastian, Landsberg, Jennifer, and Dietrich, Dimo

Published
2023
Full Text
View/download PDF

8. DNA methylation regulates TIGIT expression within the melanoma microenvironment, is prognostic for overall survival, and predicts progression-free survival in patients treated with anti-PD-1 immunotherapy

Author

Niebel, Dennis, Fröhlich, Anne, Zarbl, Romina, Fietz, Simon, de Vos, Luka, Vogt, Timo J., Dietrich, Jörn, Sirokay, Judith, Kuster, Pia, Saavedra, Gonzalo, Ramírez Valladolid, Susana, Hoffmann, Friederike, Strieth, Sebastian, Landsberg, Jennifer, and Dietrich, Dimo

Published
2022
Full Text
View/download PDF

10. Unleashing the potential of eHealth in outpatient cancer care for patients undergoing immunotherapy—a quantitative study considering patients' needs and current healthcare challenges.

Author

Holderried, Tobias A. W., Stasik, Isabel, Schmitz, Marie-Therese, Schmitz, Friederike, Meyer, Tizian K., Stauß, Leonie, Kirschner, Martin, Skowasch, Dirk, Landsberg, Jennifer, Schmid, Matthias, Brossart, Peter, and Holderried, Martin

Subjects
MOBILE apps, HEALTH literacy, SOCIAL media, SUPPORT groups, ACADEMIC medical centers, RESEARCH funding, HEALTH attitudes, CANCER patient medical care, IMMUNOTHERAPY, QUESTIONNAIRES, SEX distribution, LOGISTIC regression analysis, DIGITAL health, CANCER patients, QUANTITATIVE research, AGE distribution, DESCRIPTIVE statistics, IMMUNE checkpoint inhibitors, TELEMEDICINE, LONGITUDINAL method, ODDS ratio, RESEARCH, CONFIDENCE intervals, DATA analysis software, PATIENTS' attitudes, EDUCATIONAL attainment, BLOGS
Abstract

Background: The use of online information and communication is globally increasing in the healthcare sector. In addition to known benefits in other medical fields, possible specific potentials of eHealth lie in the monitoring of oncological patients undergoing outpatient therapy. Specifically, the treatment with immune checkpoint inhibitors (ICI) requires intensive monitoring due to various possible negative side effects. The present study explores cancer patients' perspectives on eHealth and demonstrates how eHealth applications, from the patients' point of view, can contribute to further improving outpatient immunotherapy. Methods and findings: Our multicenter study was executed at the university hospitals in Bonn and Aachen. A structured questionnaire was distributed to patients receiving outpatient immunotherapy. Contents addressed were (1) the patients' attitude towards eHealth applications, (2) the use of modern information and communications technologies (ICT) in (2a) everyday life and (2b) health-related information search including eHealth literacy, (3) the use of internet-enabled devices as well as (4) socio-demographic data. 164 patients were included in the study, of whom 39.0% were female and 61.0% male and the average age was 62.8 years. Overall, there was a high distribution of internet-enabled devices for everyday use and a great interest in integrating eHealth applications into outpatient immunotherapy. The assessment of eHealth potentials significantly depended on age. The younger participants demonstrated a broader use of modern ICT and a higher affinity for its use in outpatient immunotherapy. In some aspects, level of education and gender were also relevant factors influencing the patients' view on eHealth. Conclusion: This study demonstrates the potential for further integration of eHealth applications into outpatient immunotherapy from the patients' perspective. It indicates a dependency on age and educational level for the further integration of eHealth into patient care in oncology. Due to particular patient needs regarding age, level of education, gender and other subgroups, specific education and training as well as target-group specific digital health interventions are necessary to fully utilize the potentials of eHealth for outpatient immunotherapy. Future studies are required to specifically address target-group specific usability of eHealth applications and eHealth literacy, as well as to address information security and data protection. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

16. DNA Methylation and mRNA Expression of OX40 (TNFRSF4) and GITR (TNFRSF18, AITR) in Head and Neck Squamous Cell Carcinoma Correlates with HPV Status, Mutational Load, an Interferon-γ Signature, Signatures of Immune Infiltrates, and Survival

Author

Loick, Sophia M., Fröhlich, Anne, Gabrielpillai, Jennis, Franzen, Alina, Vogt, Timo J., Dietrich, Jörn, Wiek, Constanze, Scheckenbach, Kathrin, Strieth, Sebastian, Landsberg, Jennifer, and Dietrich, Dimo

Published
2021
Full Text
View/download PDF

18. No evidence to support the impact of migration background on treatment response rates and cancer survival: a retrospective matched-pair analysis in Germany

Author

Rüdiger, Roman, Geiser, Franziska, Ritter, Manuel, Brossart, Peter, Keyver-Paik, Mignon-Denise, Faridi, Andree, Vatter, Hartmut, Bootz, Friedrich, Landsberg, Jennifer, Kalff, Jörg C., Herrlinger, Ulrich, Kristiansen, Glen, Pietsch, Torsten, Aretz, Stefan, Thomas, Daniel, Radbruch, Lukas, Kramer, Franz-Josef, Strassburg, Christian P., Gonzalez-Carmona, Maria, Skowasch, Dirk, Essler, Markus, Schmid, Matthias, Nadal, Jennifer, Ernstmann, Nicole, Sharma, Amit, Funke, Benjamin, and Schmidt-Wolf, Ingo G. H.

Published
2021
Full Text
View/download PDF

22. CD52 mRNA expression predicts prognosis and response to immune checkpoint blockade in melanoma.

Author

de Vos‐Hillebrand, Luka, Fietz, Simon, Hillebrand, Philip, Kulcsár, Zsófi, Diop, Marie Yatou, Hollick, Sarah, Maas, Alexander Philippe, Strieth, Sebastian, Landsberg, Jennifer, and Dietrich, Dimo

Subjects
IMMUNE checkpoint proteins, GENE expression, MELANOMA, CHRONIC lymphocytic leukemia, T cells, IMMUNE response
Abstract

The immune‐modulating protein CD52 attenuates lymphocyte function and is associated with autoimmune disorders, for example, multiple sclerosis (MS). CD52 represents a therapeutic target in MS and chronic lymphocytic leukemia (CLL). Its expression has prognostic and predictive value in CLL and is prognostic in breast cancer. Its significance in melanoma is unclear. We analyzed CD52 mRNA expression data from tumor bulk tissues of N = 445 untreated melanoma patients from The Cancer Genome Atlas (TCGA) Research Network and of N = 121 melanoma patients undergoing anti‐PD‐1 immune checkpoint blockade (ICB) with regard to outcome (overall survival [OS], disease control [DC], and progression‐free survival [PFS]), single‐cell RNA‐Seq data of N = 4645 cells from N = 19 melanoma tissues, and N = 15,457 cells from normal skin provided by N = 5 donors. Higher CD52 mRNA expression was associated with favorable OS (hazard ratio (HR) = 0.820, [95% CI 0.734–0.916], p <.001) in non‐ICB‐treated melanoma and with PFS (HR = 0.875, [95% CI 0.775–0.989], p =.033) and DC (p =.005) in ICB‐treated melanoma. CD52 expression correlated significantly with distinct immune cell subsets and correlated negatively with immune checkpoint expression in T cells. Moreover, our results suggest CD52 expression by a certain type of tissue‐resident macrophages. CD52 mRNA was expressed in a small subgroup (8%) of immune checkpoint coexpressing melanoma cells. CD52 expression is associated with features of ICB response in melanoma. Concomitant ICB and anti‐CD52 treatment requires critical review. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

24. Deep learning based histological classification of adnex tumors

Author

Jansen, Philipp, primary, Arrastia, Jean Le’Clerc, additional, Baguer, Daniel Otero, additional, Schmidt, Maximilian, additional, Landsberg, Jennifer, additional, Wenzel, Jörg, additional, Emberger, Michael, additional, Schadendorf, Dirk, additional, Hadaschik, Eva, additional, Maass, Peter, additional, and Griewank, Klaus Georg, additional

Published
2023
Full Text
View/download PDF

25. PD-L1 ( CD274 ) promoter hypomethylation predicts immunotherapy response in metastatic urothelial carcinoma

Author

Klümper, Niklas, primary, Wüst, Lennert, additional, Saal, Jonas, additional, Ralser, Damian J., additional, Zarbl, Romina, additional, Jarczyk, Jonas, additional, Breyer, Johannes, additional, Sikic, Danijel, additional, Wullich, Bernd, additional, Bolenz, Christian, additional, Roghmann, Florian, additional, Hölzel, Michael, additional, Ritter, Manuel, additional, Strieth, Sebastian, additional, Hartmann, Arndt, additional, Erben, Philipp, additional, Wirtz, Ralph M., additional, Landsberg, Jennifer, additional, Dietrich, Dimo, additional, and Eckstein, Markus, additional

Published
2023
Full Text
View/download PDF

27. Higher number of multidisciplinary tumor board meetings per case leads to improved clinical outcome

Author

Freytag, Marius, Herrlinger, Ulrich, Hauser, Stefan, Bauernfeind, Franz G., Gonzalez-Carmona, Maria A., Landsberg, Jennifer, Buermann, Jens, Vatter, Hartmut, Holderried, Tobias, Send, Thorsten, Schumacher, Martin, Koscielny, Arne, Feldmann, Georg, Heine, Mario, Skowasch, Dirk, Schäfer, Niklas, Funke, Benjamin, Neumann, Michael, and Schmidt-Wolf, Ingo G. H.

Published
2020
Full Text
View/download PDF

30. Pharmazeutische Behandlung der akuten Radiodermatitis in der deutschsprachigen strahlentherapeutischen Gemeinschaft: Pharmaceutical management of acute radiation dermatitis in the German speaking radiation oncology community.

Author

Layer, Julian P., Layer, Katharina, Glasmacher, Andrea R., Sarria, Gustavo R., Böhner, Alexander M. C., Layer, Yonah L., Dejonckheere, Cas S., Wiegreffe, Shari, Nour, Youness, Caglayan, Lara, Grau, Franziska, Feyer, Petra, Baumert, Brigitta G., Baumann, René, Krug, David, Scafa, Davide, Leitzen, Christina, Landsberg, Jennifer, Giordano, Frank A., and Schmeel, Leonard Christopher

Abstract

Copyright of Journal der Deutschen Dermatologischen Gesellschaft is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Published
2024
Full Text
View/download PDF

31. Pharmaceutical management of acute radiation dermatitis in the German speaking radiation oncology community.

Author

Layer, Julian P., Layer, Katharina, Glasmacher, Andrea R., Sarria, Gustavo R., Böhner, Alexander M. C., Layer, Yonah L., Dejonckheere, Cas S., Wiegreffe, Shari, Nour, Youness, Caglayan, Lara, Grau, Franziska, Feyer, Petra, Baumert, Brigitta G., Baumann, René, Krug, David, Scafa, Davide, Leitzen, Christina, Landsberg, Jennifer, Giordano, Frank A., and Schmeel, Leonard Christopher

Abstract

Summary: Background: Radiation dermatitis (RD) remains the most common side effect in radiation therapy (RT) with various pharmaceutical options available for prevention and treatment. We sought to determine pharmaceutical management patterns of radiation dermatitis among radiation oncology professionals. Methods: We conducted a survey on RD among the German‐speaking community of radiation oncologists inquiring for their opinion on preventive and therapeutic pharmaceutical approaches for acute RD. Results: 244 health professionals participated. Dexpanthenol lotion is the agent most widely used both for prevention (53.0%) and treatment (76.9%) of RD, followed by urea (29.8%) for prevention and corticosteroids (46.9%) for treatment. A wide range of substances is used by participants, though the overall experience with them is rather limited. 32.5% of participants do generally not recommend any preventative treatment. 53.4% of participants recommend alternative medicine for RD management. While seldomly used, corticosteroids were considered most effective in RD therapy, followed by dexpanthenol and low‐level laser therapy. A majority of participants prefers moist over dry treatment of moist desquamation and 43.8% prescribe antiseptics. Conclusions: Pharmaceutical management of RD in the German‐speaking radiation oncology community remains controversial, inconsistent, and partially not supported by evidence‐based medicine. Stronger evidence level and interdisciplinary consensus is required amongst practitioners to improve these care patterns. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

32. Supplementary Table 1 from Immune Cell–Poor Melanomas Benefit from PD-1 Blockade after Targeted Type I IFN Activation

Author

Bald, Tobias, primary, Landsberg, Jennifer, primary, Lopez-Ramos, Dorys, primary, Renn, Marcel, primary, Glodde, Nicole, primary, Jansen, Philipp, primary, Gaffal, Evelyn, primary, Steitz, Julia, primary, Tolba, Rene, primary, Kalinke, Ulrich, primary, Limmer, Andreas, primary, Jönsson, Göran, primary, Hölzel, Michael, primary, and Tüting, Thomas, primary

Published
2023
Full Text
View/download PDF

33. Supplementary Figures 1-2 from Immune Cell–Poor Melanomas Benefit from PD-1 Blockade after Targeted Type I IFN Activation

Author

Bald, Tobias, primary, Landsberg, Jennifer, primary, Lopez-Ramos, Dorys, primary, Renn, Marcel, primary, Glodde, Nicole, primary, Jansen, Philipp, primary, Gaffal, Evelyn, primary, Steitz, Julia, primary, Tolba, Rene, primary, Kalinke, Ulrich, primary, Limmer, Andreas, primary, Jönsson, Göran, primary, Hölzel, Michael, primary, and Tüting, Thomas, primary

Published
2023
Full Text
View/download PDF

34. Data from Immune Cell–Poor Melanomas Benefit from PD-1 Blockade after Targeted Type I IFN Activation

Author

Bald, Tobias, primary, Landsberg, Jennifer, primary, Lopez-Ramos, Dorys, primary, Renn, Marcel, primary, Glodde, Nicole, primary, Jansen, Philipp, primary, Gaffal, Evelyn, primary, Steitz, Julia, primary, Tolba, Rene, primary, Kalinke, Ulrich, primary, Limmer, Andreas, primary, Jönsson, Göran, primary, Hölzel, Michael, primary, and Tüting, Thomas, primary

Published
2023
Full Text
View/download PDF

35. Table S6 from MAPK Signaling and Inflammation Link Melanoma Phenotype Switching to Induction of CD73 during Immunotherapy

Author

Reinhardt, Julia, primary, Landsberg, Jennifer, primary, Schmid-Burgk, Jonathan L., primary, Ramis, Bartomeu Bibiloni, primary, Bald, Tobias, primary, Glodde, Nicole, primary, Lopez-Ramos, Dorys, primary, Young, Arabella, primary, Ngiow, Shin Foong, primary, Nettersheim, Daniel, primary, Schorle, Hubert, primary, Quast, Thomas, primary, Kolanus, Waldemar, primary, Schadendorf, Dirk, primary, Long, Georgina V., primary, Madore, Jason, primary, Scolyer, Richard A., primary, Ribas, Antoni, primary, Smyth, Mark J., primary, Tumeh, Paul C., primary, Tüting, Thomas, primary, and Hölzel, Michael, primary

Published
2023
Full Text
View/download PDF

36. Tables S1, S2, S4, S8, S9 from MAPK Signaling and Inflammation Link Melanoma Phenotype Switching to Induction of CD73 during Immunotherapy

Author

Reinhardt, Julia, primary, Landsberg, Jennifer, primary, Schmid-Burgk, Jonathan L., primary, Ramis, Bartomeu Bibiloni, primary, Bald, Tobias, primary, Glodde, Nicole, primary, Lopez-Ramos, Dorys, primary, Young, Arabella, primary, Ngiow, Shin Foong, primary, Nettersheim, Daniel, primary, Schorle, Hubert, primary, Quast, Thomas, primary, Kolanus, Waldemar, primary, Schadendorf, Dirk, primary, Long, Georgina V., primary, Madore, Jason, primary, Scolyer, Richard A., primary, Ribas, Antoni, primary, Smyth, Mark J., primary, Tumeh, Paul C., primary, Tüting, Thomas, primary, and Hölzel, Michael, primary

Published
2023
Full Text
View/download PDF

37. Supplementary Figures S1-S6 from Targeting Adenosine in BRAF-Mutant Melanoma Reduces Tumor Growth and Metastasis

Author

Young, Arabella, primary, Ngiow, Shin Foong, primary, Madore, Jason, primary, Reinhardt, Julia, primary, Landsberg, Jennifer, primary, Chitsazan, Arash, primary, Rautela, Jai, primary, Bald, Tobias, primary, Barkauskas, Deborah S., primary, Ahern, Elizabeth, primary, Huntington, Nicholas D., primary, Schadendorf, Dirk, primary, Long, Georgina V., primary, Boyle, Glen M., primary, Hölzel, Michael, primary, Scolyer, Richard A., primary, and Smyth, Mark J., primary

Published
2023
Full Text
View/download PDF

38. Legends to Suppl. Figures from MAPK Signaling and Inflammation Link Melanoma Phenotype Switching to Induction of CD73 during Immunotherapy

Author

Reinhardt, Julia, primary, Landsberg, Jennifer, primary, Schmid-Burgk, Jonathan L., primary, Ramis, Bartomeu Bibiloni, primary, Bald, Tobias, primary, Glodde, Nicole, primary, Lopez-Ramos, Dorys, primary, Young, Arabella, primary, Ngiow, Shin Foong, primary, Nettersheim, Daniel, primary, Schorle, Hubert, primary, Quast, Thomas, primary, Kolanus, Waldemar, primary, Schadendorf, Dirk, primary, Long, Georgina V., primary, Madore, Jason, primary, Scolyer, Richard A., primary, Ribas, Antoni, primary, Smyth, Mark J., primary, Tumeh, Paul C., primary, Tüting, Thomas, primary, and Hölzel, Michael, primary

Published
2023
Full Text
View/download PDF

39. Supplementary Data from Inhibition of Melanoma Cell–Intrinsic Tim-3 Stimulates MAPK-Dependent Tumorigenesis

Author

Schatton, Tobias, primary, Itoh, Yuta, primary, Martins, Christina, primary, Rasbach, Erik, primary, Singh, Praveen, primary, Silva, Mariana, primary, Mucciarone, Kyla, primary, Heppt, Markus V., primary, Geddes-Sweeney, Jenna, primary, Stewart, Kate, primary, Brandenburg, Anne, primary, Liang, Jennifer, primary, Dimitroff, Charles J., primary, Mihm, Martin C., primary, Landsberg, Jennifer, primary, Schlapbach, Christoph, primary, Lian, Christine G., primary, Murphy, George F., primary, Kupper, Thomas S., primary, Ramsey, Matthew R., primary, and Barthel, Steven R., primary

Published
2023
Full Text
View/download PDF

40. Data from Targeting Adenosine in BRAF-Mutant Melanoma Reduces Tumor Growth and Metastasis

Author

Young, Arabella, primary, Ngiow, Shin Foong, primary, Madore, Jason, primary, Reinhardt, Julia, primary, Landsberg, Jennifer, primary, Chitsazan, Arash, primary, Rautela, Jai, primary, Bald, Tobias, primary, Barkauskas, Deborah S., primary, Ahern, Elizabeth, primary, Huntington, Nicholas D., primary, Schadendorf, Dirk, primary, Long, Georgina V., primary, Boyle, Glen M., primary, Hölzel, Michael, primary, Scolyer, Richard A., primary, and Smyth, Mark J., primary

Published
2023
Full Text
View/download PDF

41. Data from Inhibition of Melanoma Cell–Intrinsic Tim-3 Stimulates MAPK-Dependent Tumorigenesis

Author

Schatton, Tobias, primary, Itoh, Yuta, primary, Martins, Christina, primary, Rasbach, Erik, primary, Singh, Praveen, primary, Silva, Mariana, primary, Mucciarone, Kyla, primary, Heppt, Markus V., primary, Geddes-Sweeney, Jenna, primary, Stewart, Kate, primary, Brandenburg, Anne, primary, Liang, Jennifer, primary, Dimitroff, Charles J., primary, Mihm, Martin C., primary, Landsberg, Jennifer, primary, Schlapbach, Christoph, primary, Lian, Christine G., primary, Murphy, George F., primary, Kupper, Thomas S., primary, Ramsey, Matthew R., primary, and Barthel, Steven R., primary

Published
2023
Full Text
View/download PDF

42. Supplementary Figure 1 to 7 from MAPK Signaling and Inflammation Link Melanoma Phenotype Switching to Induction of CD73 during Immunotherapy

Author

Reinhardt, Julia, primary, Landsberg, Jennifer, primary, Schmid-Burgk, Jonathan L., primary, Ramis, Bartomeu Bibiloni, primary, Bald, Tobias, primary, Glodde, Nicole, primary, Lopez-Ramos, Dorys, primary, Young, Arabella, primary, Ngiow, Shin Foong, primary, Nettersheim, Daniel, primary, Schorle, Hubert, primary, Quast, Thomas, primary, Kolanus, Waldemar, primary, Schadendorf, Dirk, primary, Long, Georgina V., primary, Madore, Jason, primary, Scolyer, Richard A., primary, Ribas, Antoni, primary, Smyth, Mark J., primary, Tumeh, Paul C., primary, Tüting, Thomas, primary, and Hölzel, Michael, primary

Published
2023
Full Text
View/download PDF

43. Supplementary Methods from MAPK Signaling and Inflammation Link Melanoma Phenotype Switching to Induction of CD73 during Immunotherapy

Author

Reinhardt, Julia, primary, Landsberg, Jennifer, primary, Schmid-Burgk, Jonathan L., primary, Ramis, Bartomeu Bibiloni, primary, Bald, Tobias, primary, Glodde, Nicole, primary, Lopez-Ramos, Dorys, primary, Young, Arabella, primary, Ngiow, Shin Foong, primary, Nettersheim, Daniel, primary, Schorle, Hubert, primary, Quast, Thomas, primary, Kolanus, Waldemar, primary, Schadendorf, Dirk, primary, Long, Georgina V., primary, Madore, Jason, primary, Scolyer, Richard A., primary, Ribas, Antoni, primary, Smyth, Mark J., primary, Tumeh, Paul C., primary, Tüting, Thomas, primary, and Hölzel, Michael, primary

Published
2023
Full Text
View/download PDF

44. Supplementary Methods, Table, and Legends from Targeting Adenosine in BRAF-Mutant Melanoma Reduces Tumor Growth and Metastasis

Author

Young, Arabella, primary, Ngiow, Shin Foong, primary, Madore, Jason, primary, Reinhardt, Julia, primary, Landsberg, Jennifer, primary, Chitsazan, Arash, primary, Rautela, Jai, primary, Bald, Tobias, primary, Barkauskas, Deborah S., primary, Ahern, Elizabeth, primary, Huntington, Nicholas D., primary, Schadendorf, Dirk, primary, Long, Georgina V., primary, Boyle, Glen M., primary, Hölzel, Michael, primary, Scolyer, Richard A., primary, and Smyth, Mark J., primary

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results